Industry/Regulatory Developments
Approved peptide medicines are defined by their labels
Tesamorelin, bremelanotide, semaglutide, and tirzepatide each became a specific product with an indication. A related research…
Archive
Month: April 2026
Industry/Regulatory Developments
Compounding rules and research-supply catalogs are different legal stories
FDA bulk-drug-substance lists govern compounding. A research-chemical storefront is not a pharmacy exception and not a…
Industry/Regulatory Developments
Tesamorelin reduced liver fat in a defined HIV trial. The indication did not widen by itself.
Stanley and colleagues reported less visceral fat and less liver fat in a randomized trial. The…